Prosonix and Mylan in deal for Flixotide and Flovent generics

15 April 2014

Prosonix, a UK-based company which is developing a portfolio of inhaled “Respiratory Medicines by Design,” has entered into a global licensing agreement with US generics major Mylan (Nasdaq: MYL) for its leading inhaled respiratory products, PSX1001 and PSX1050.

PSX1001 and PSX1050, which are the first products to emerge from Prosonix' innovative and proprietary particle engineering platform, are being developed as generic versions to GlaxoSmithKline's pressurised metered dose inhalers (pMDI) Flixotide and Flovent, respectively. Flixotide and Flovent contain the active ingredient fluticasone propionate, a potent inhaled corticosteroid, and are indicated for the treatment of asthma.

Branded sales of the drugs were $1.3 billion in 2013

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK